GPE
National Resilience Lays Off 120 Employees at Former Bluebird Bio Gene Therapy Facility in Durham, North Carolina
National Resilience, Layoffs, Gene Therapy, Bluebird Bio, Durham/ North Carolina, Biotech Industry, CDMO (Contract Development and Manufacturing Organization)
Transcarent Acquires Accolade for $621 Million in Strategic Healthcare Deal
Transcarent, Accolade, healthcare acquisition, personalized healthcare, AI-powered healthcare, healthcare technology
Metsera Advances with Positive Phase IIa Results for Monthly GLP-1RA Dosing
Metsera, GLP-1RA, MET-097i, obesity treatment, monthly dosing, weight loss, clinical trials
WuXi Biologics Divests Irish Vaccine Facility to Merck for $500 Million Amid Strategic Shift
WuXi Biologics, Merck, vaccine manufacturing facility, Dundalk, Ireland, asset sale, strategic shift, regulatory changes, Biosecure Act
Eli Lilly’s Zepbound Receives FDA Approval as First Prescription Drug for Moderate-to-Severe Obstructive Sleep Apnea in Adults with Obesity
GLP-1, Obstructive Sleep Apnea (OSA), Obesity, Zepbound, Tirzepatide, FDA Approval, Sleep Disorder Treatment
Congress Passes Slimmed-Down Continuing Resolution, Extends Telehealth Flexibilities and Includes PBM Reform
Continuing Resolution, Telehealth Flexibilities, PBM Reform, Healthcare Package, Medicare, Medicaid
KdT Ventures Launches New Biotech Startup to Develop NGM Bio’s Rare Disease Drug Candidate NGM313
KdT Ventures, NGM Bio, NGM313, Rare Disease, Biotechnology, Drug Development, Phase 2 Trial
UCB and Novartis Discontinue Development of Parkinson’s Disease Drug After Phase 2 Failure
UCB, Novartis, Parkinson’s disease, drug development, Phase 2 failure, UCB0599, UCB7853
FDA Approves Expanded Use of VTAMA and Nemluvio for Atopic Dermatitis Treatment
FDA approval, atopic dermatitis, VTAMA, Nemluvio, Galderma, Organon, dermatology, skin conditions
Cancer Pipelines Contract: Incyte and iTeos Discontinue Drug Candidates Amid Underwhelming Clinical Results
Incyte, iTeos, cancer pipelines, drug candidates, clinical trials, disappointing data, pipeline cuts, oncology research.